Investors

Corporate Overview Press Releases Investor Events Stock Information SEC Filings

Financials

Snapshot Trading Statistics

Other Information

Email Alerts

Press Releases

Print Page Print Page        E-mail Page Email Page        RSS Feeds RSS        E-mail Alerts Email Alerts        Financial Tear Sheet Tear Sheet
Keyword Search
 
2013 | 2012 | 2011 | 2010 | 2009 | 2008
DateTitle 
12/11/08Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA FeedbackPrinter Friendly Version
12/04/08Alkermes Initiates Clinical Trial for ALKS 33, a Novel Oral Molecule with Potential Benefits in Addiction and Other CNS DisordersPrinter Friendly Version
12/01/08Alkermes Regains Full Commercialization Rights to VIVITROL(R) in USPrinter Friendly Version
11/25/08Alkermes' Corporate Presentation to be Webcast at JPMorgan SMid Cap ConferencePrinter Friendly Version
11/24/08Alkermes' Corporate Presentation to be Webcast at the NASDAQ Investor ProgramPrinter Friendly Version
11/17/08Alkermes Presents Positive Preclinical Data on Novel, Proprietary Molecule Designed to Improve Outcomes for Patients Taking Opioid AnalgesicsPrinter Friendly Version
11/11/08Alkermes' Corporate Presentation to be Webcast at Lazard Capital Markets Fifth Annual Healthcare ConferencePrinter Friendly Version
11/06/08Alkermes Announces Second Quarter Fiscal 2009 ResultsPrinter Friendly Version
10/30/08Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2009Printer Friendly Version
10/09/08FDA Approves New Injection Site for RISPERDAL(R) CONSTA(R) for Schizophrenia TreatmentPrinter Friendly Version
10/08/08David Anstice Elected to Alkermes' Board of DirectorsPrinter Friendly Version
09/16/08Alkermes' Corporate Presentation to be Webcast at the UBS Global Life Sciences ConferencePrinter Friendly Version
09/02/08Alkermes' Corporate Presentation to be Webcast at Two Upcoming Investor ConferencesPrinter Friendly Version
08/29/08Alkermes' Corporate Presentation to be Webcast at the Thomas Weisel Partners Healthcare ConferencePrinter Friendly Version
08/07/08Alkermes Announces First Quarter Fiscal 2009 Results and Raises Financial Expectations for Fiscal 2009Printer Friendly Version
08/04/08Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in RussiaPrinter Friendly Version
07/31/08Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2009Printer Friendly Version
07/24/08Supplemental New Drug Application for RISPERDAL(R)
CONSTA(R) Submitted to the FDA for the Treatment of Bipolar Disorder		Printer Friendly Version
07/14/08Alkermes Presents Positive Preclinical Data on Naltrexone for Extended-Release Injectable Suspension at Annual Meeting of Controlled Release SocietyPrinter Friendly Version
07/01/08Alkermes Presents Positive Data on Proprietary Molecules Targeting Opioid ReceptorsPrinter Friendly Version
06/26/08Alkermes Initiates Phase 3 Clinical Study of VIVITROL(R) for the Treatment of Opioid DependencePrinter Friendly Version
06/16/08Alkermes Expands Common Stock Repurchase Program and Raises Fiscal Year 2009 Financial ExpectationsPrinter Friendly Version
06/09/08After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008Printer Friendly Version
06/07/08Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, WeightPrinter Friendly Version
05/27/08Alkermes' Corporate Presentation to be Webcast at the Friedman, Billings, Ramsey Spring Investor ConferencePrinter Friendly Version
05/22/08Alkermes Reports Financial Results for Fiscal 2008 and Provides Financial Expectations for Fiscal 2009Printer Friendly Version
05/15/08Alkermes to Host Conference Call to Discuss Fiscal Year 2008 Financial ResultsPrinter Friendly Version
05/08/08Alkermes' Corporate Presentation to be Webcast at the Banc of America Securities Health Care ConferencePrinter Friendly Version
05/06/08Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical StudyPrinter Friendly Version
04/28/08Alkermes' Corporate Presentation to Be Webcast at the Morgan Stanley Global Healthcare Unplugged ConferencePrinter Friendly Version
04/14/08Supplemental New Drug Application for RISPERDAL(R) CONSTA(R) Submitted to the FDA for the Treatment of Frequently Relapsing Bipolar DisorderPrinter Friendly Version
03/19/08Alkermes Announces RestructuringPrinter Friendly Version
03/13/08Alkermes' Corporate Presentation to Be Webcast at the Cowen and Company Health Care ConferencePrinter Friendly Version
03/07/08Alkermes Receives Notice from Eli Lilly Terminating Inhaled Insulin ProgramPrinter Friendly Version
03/07/08Alkermes Provides Update on Inhaled Insulin ProgramPrinter Friendly Version
02/07/08Alkermes Announces $60 Million Accelerated Share Repurchase ProgramPrinter Friendly Version
02/07/08Alkermes Announces Third Quarter Fiscal 2008 ResultsPrinter Friendly Version
02/04/08Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar DisorderPrinter Friendly Version
01/31/08Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2008Printer Friendly Version
01/29/08Alkermes' Corporate Presentation to be Webcast at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device ConferencePrinter Friendly Version
01/07/08Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CISPrinter Friendly Version
01/02/08Alkermes' Corporate Presentation to be Webcast at JPMorgan Annual Healthcare ConferencePrinter Friendly Version